Feasibility of sonothrombolysis in the ambulance for ST-elevation myocardial infarction.

Int J Cardiovasc Imaging

Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Published: May 2022

AI Article Synopsis

  • Patients with ST-elevation myocardial infarction (STEMI) require quick restoration of blood flow, and a new method called sonothrombolysis uses ultrasound and microbubbles to break down clots and improve blood circulation.
  • A study tested the feasibility of using sonothrombolysis in ambulances for STEMI patients, assessing how long the treatment lasted and its safety during patient transport.
  • Out of twelve screened patients, three were treated; the method showed promising results without complications, highlighting the need for larger clinical trials to confirm its effectiveness and safety.

Article Abstract

Patients with ST-elevation myocardial infarction (STEMI) due to coronary occlusion require immediate restoration of epicardial and microvascular blood flow. A potentially new reperfusion method is the use of ultrasound and microbubbles, also called sonothrombolysis. The oscillation and collapse of intravenously administered microbubbles upon exposure to high mechanical index (MI) ultrasound pulses results in thrombus dissolution and stimulates nitric oxide-mediated increases in tissue perfusion. The aim of this study was to assess feasibility of sonothrombolysis in the ambulance for STEMI patients. Patients presenting with chest pain and ST-elevations on initial electrocardiogram were included. Sonothrombolysis was applied in the ambulance during patient transfer to the percutaneous coronary intervention (PCI) center. Feasibility was assessed based on duration of sonothrombolysis treatment and number of high MI pulses applied. Vital parameters, ST-resolution, pre- and post-PCI coronary flow and cardiovascular magnetic resonance images were analyzed. Follow up was performed at six months after STEMI. Twelve patients were screened, of which three patients were included in the study. Sonothrombolysis duration and number of high MI pulses ranged between 12 and 17 min and 32-60 flashes respectively. No arrhythmias or changes in vital parameters were observed during and directly after sonothrombolysis, although one patient developed in-hospital ventricular fibrillation 20 min after sonothrombolysis completion but before PCI. In one case, sonothrombolysis on top of regular pre-hospital care resulted in reperfusion before PCI. This is the first report on the feasibility of performing sonothrombolysis to treat myocardial infarction in an ambulance. To assess efficacy and safety of pre-hospital sonothrombolysis, clinical trials with greater patient numbers should be performed. EU Clinical Trials Register (identifier: 2019-001883-31), registered 2020-02-25.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10554-021-02487-7DOI Listing

Publication Analysis

Top Keywords

myocardial infarction
12
sonothrombolysis
10
feasibility sonothrombolysis
8
sonothrombolysis ambulance
8
st-elevation myocardial
8
number high
8
high pulses
8
vital parameters
8
clinical trials
8
patients
5

Similar Publications

Cardiomyocytes (CMs) lost during ischemic cardiac injury cannot be replaced due to their limited proliferative capacity. Calcium is an important signal transducer that regulates key cellular processes, but its role in regulating CM proliferation is incompletely understood. Here we show a robust pathway for new calcium signaling-based cardiac regenerative strategies.

View Article and Find Full Text PDF

MAFLD as a predictor of adverse cardiovascular events among CHD patients with LDL-C<1.8 mmol/L.

Nutr Metab Cardiovasc Dis

November 2024

Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China. Electronic address:

Background And Aims: Patients receiving statin therapy still suffer from adverse cardiovascular events. Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a newly proposed concept that shares common metabolic risk factors with cardiovascular disease. This study aimed to investigate the association between MAFLD and adverse cardiovascular outcomes in coronary heart disease (CHD) patients with LDL-C<1.

View Article and Find Full Text PDF

From Escalate to Elevate: A New Paradigm for Comprehensive Cardiogenic Shock Management.

Can J Cardiol

January 2025

Ted Rogers Centre for Heart Research, University Health Network, Toronto, ON, Canada; Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada. Electronic address:

Patients with cardiogenic shock (CS) present with critical hemodynamic compromise with low cardiac output (CO) resulting in end-organ dysfunction. Prognosis is closely related to the severity of shock and treatment of patients with CS is resource intensive. In this review, we consider the current treatment paradigms alongside the evidence that underpins them.

View Article and Find Full Text PDF

The possibility of using an oxygen-nitrous oxide mixture for prolonged hypothermic preservation of rat heart for 24 hours was investigated. A comparative analysis of restoration of functional activity of hearts in the groups of 24-hour preservation at +4°C with different gases (O, N) and gas mixtures (CO+O, NO+O, N+O, NO+N) was carried out. It was shown that the presence of oxygen in the gas mixture was the key factor for heart preservation.

View Article and Find Full Text PDF

Does Rose angina in midlife women matter? Further evidence from the Royal College of General Practitioners' Oral Contraception Study.

Maturitas

January 2025

Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK. Electronic address:

Background And Aims: Globally, ischaemic heart disease (IHD) is a leading cause of death among women; however, disparities remain in the diagnosis and treatment of IHD between females and males. There is limited evidence about mortality risks among women with symptoms of IHD who remain undiagnosed. We re-examined the mortality risks in midlife women who completed the Rose Angina Questionnaire, among a subset of the Royal College of General Practitioners' Oral Contraception Study cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!